Qualigen Therapeutics, Inc.

QLGN

US74754R2022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
0.305 ^USD	+6.09%		+4.10%	-44.55%

04-16	Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?	CI
04-08	Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ritter Pharmaceuticals, Inc. has Changed its Name to Qualigen Therapeutics, Inc

May 19, 2020 at 04:25 pm

Ritter Pharmaceuticals, Inc. changed its name to Qualigen Therapeutics, Inc.

Latest news about Qualigen Therapeutics, Inc.

Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?	04-16	CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
Qualigen Therapeutics, Inc. Enters into A Termination Agreement with Pan-RAS Holdings, Inc	03-28	CI
Qualigen Therapeutics, Inc. announced that it has received $0.55 million in funding from Alpha Capital Anstalt	02-26	CI
Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt	02-25	CI
Qualigen Therapeutics, Inc. Enters into A License and Sublicense Agreement with Pan-RAS Holdings, Inc	02-22	CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors	11-07	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M	23-08-15	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors	23-08-01	CI
Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. for $5.8 million.	23-07-23	CI
Biosynex: acquisition of Qualigen in the United States	23-07-21	CF
Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director	23-06-26	CI
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology 2023 Annual Meeting	23-06-05	CI
Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023	23-05-19	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q1 Revenue $1.6M	23-05-16	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Posts Q4 Revenue $5M	23-05-02	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Qualigen Therapeutics Receives Nasdaq's Non-Compliance Notice	23-04-24	MT
Qualigen Therapeutics Says QN-302 US Patent Granted; Shares Rise	23-03-21	MT
Qualigen Therapeutics, Inc. to Present Five Posters At the American Association for Cancer Research Annual Meeting 2023	23-03-15	CI
Qualigen Therapeutics, Inc. Announces Publication of Key Data in the Peer-Reviewed Journal Molecules	23-03-08	CI
Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302	23-01-24	CI

Chart Qualigen Therapeutics, Inc.

Duration

Period

More charts

Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Companyâs business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genesâ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUALIGEN THERAPEUTICS, INC.	-44.55%	1.92M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research

Qualigen Therapeutics, Inc.

Equities

QLGN

US74754R2022

Biotechnology & Medical Research

Ritter Pharmaceuticals, Inc. has Changed its Name to Qualigen Therapeutics, Inc

Latest news about Qualigen Therapeutics, Inc.

Chart Qualigen Therapeutics, Inc.

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research